Краткое изложение проекта федеральных клинических рекомендаций по остеопорозу

Представлено краткое изложение проекта федеральных клинических рекомендаций по остеопорозу, разработанных членами Российской ассоциации эндокринологов, Российской ассоциации по остеопорозу, Ассоциации ревматологов России, Ассоциации травматологов-ортопедов России, Российской ассоциации по менопаузе и Российской ассоциации геронтологов и гериатров. Рекомендации разработаны с позиций доказательной медицины, в соответствии с требованиями к составлению клинических рекомендаций Минздрава России, опубликованными в 2019 г. Значительное место в изложении отведено скринингу первичного остеопороза у взрослых, дифференциальной диагностике с другими метаболическими заболеваниями скелета, современным методам диагностики остеопороза, принципам назначения патогенетического лечения, особенности последовательной и комбинированной терапии, профилактики заболевания и реабилитации. Клинические рекомендации полезны будут как врачам общей практики и терапевтам, так и узким специалистам, прежде всего эндокринологам, ревматологам, травматологам-ортопедам, нефрологам, акушерам-гинекологам и неврологам, так как остеопороз является мультифакториальным и мультидисциплинарным заболеванием.

1. Kanis JA, on behalf of the World Health Organization Scientific Group. Technical Report. WHO Collaborating Centre, University of Sheffield; UK: 2008b. [Accessed 12 May 2018]. Assessment of osteoporosis at the primary health-care level. https://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf.

2. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. The American Journal of Medicine. 1993;94(6):646-650. doi: https://doi.org/10.1016/0002-9343(93)90218-e.

3. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Проблемы Эндокринологии. - 2017. - Т. 63. - №6. - C. 392-426.doi: https://doi.org/10.14341/probl2017636392-426

4. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016 — Executive Summary. Endocr. Pract. 2016;22(9):1111-1118. doi: https://doi.org/10.4158/ep161435.esgl.

5. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2018;30(1):3-44. doi: https://doi.org/10.1007/s00198-018-4704-5.

6. Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Ann. Pharmacother. 2016;33(12):13771378. doi: https://doi.org/10.1177/106002809903301207.

7. American Association of Orthopedic Surgeons. Orthopaedic Care of Patients with Fragility Fractures (Revised September 2016). Position Statement #1159. Rosemont, 2009.

8. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. The Lancet. 2018;391(10122):741-747. doi: https://doi.org/10.1016/s0140-6736(17)32640-5.

9. Turner DA, Khioe RFS, Shepstone L, et al. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J. Bone Miner. Res. 2018;33(5):845-851. doi: https://doi.org/10.1002/jbmr.3381.

10. Lindsay R. Risk of New Vertebral Fracture in the Year Following a Fracture. JAMA. 2001;285(3):320. doi: https://doi.org/10.1001/jama.285.3.320.

11. Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. J. Bone Miner. Res. 2012;27(3):645-653. doi: https://doi.org/10.1002/jbmr.1476.

12. Edwards BJ, Bunta AD, Simonelli C, et al. Prior Fractures are Common in Patients with Subsequent Hip Fractures. Clin. Orthop. Relat. Res. 2007;461:226-230. doi: https://doi.org/10.1097/BLO.0b013e3180534269.

13. Ross PD. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women. Ann. Intern. Med. 1991;114(11):919. doi: https://doi.org/10.7326/0003-4819-114-11-919.

14. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J. Bone Miner. Res. 2009;9(8):1137-1141. doi: https://doi.org/10.1002/jbmr.5650090802.

15. Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications. J. Bone Miner. Res. 2009;24(4):702-709. doi: https://doi.org/10.1359/jbmr.081207.

16. Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014;63(12):1480-1490. doi: https://doi.org/10.1016/j.metabol.2014.09.002.

17. Schousboe JT, Ensrud KE, Nyman JA, et al. Potential costeffective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for aminobisphosphonate therapy. Osteoporos. Int. 2005;16(12):1883-1893. doi: https://doi.org/10.1007/s00198-005-1956-7.

18. Lesnyak O, Ershova O, Belova K, et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Archives of Osteoporosis. 2012;7(1-2):67-73. doi: https://doi.org/10.1007/s11657-012-0082-3.

19. Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX. Archives of Osteoporosis. 2016;11(1). doi: https://doi.org/10.1007/s11657-016-0278-z.

20. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos. Int. 2014;25(10):2359-2381. doi: https://doi.org/10.1007/s00198-014-2794-2.

21. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos. Int. 2008;19(10):1395-1408. doi: https://doi.org/10.1007/s00198-008-0712-1.

22. Kanis JA, Johnell O, De Laet C, et al. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. J. Bone Miner. Res. 2002;17(7):1237-1244. doi: https://doi.org/10.1359/jbmr.2002.17.7.1237.

23. De Laet CEDH, Van Hout BA, Burger H, et al. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study. J. Bone Miner. Res. 2009;13(10):1587-1593. doi: https://doi.org/10.1359/jbmr.1998.13.10.1587.

24. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. Osteoporos. Int. 1997;7(4):390-406. doi: https://doi.org/10.1007/bf01623782.

25. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2012;24(1):23-57. doi: https://doi.org/10.1007/s00198-012-2074-y.

26. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoidinduced osteoporosis. Osteoporos. Int. 2012;23(9):2257-2276. doi: https://doi.org/10.1007/s00198-012-1958-1.

27. Алексеева Л.И., Баранова И.А., Белова К.Ю., и др. Клинические рекомендации по профилактике и ведению больных с остеопорозом. — Ярославль: Литера; 2012. — С. 23.

28. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available from: https://iscd.app.box.com/s/ 1fa65hdehfbzgfs0x0xg3bcporv59ylo.

29. Kanis JA, Johnell O, Oden A, et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 2008;19(4):385-397. doi: https://doi.org/10.1007/s00198-007-0543-5.

30. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 2011;22(3):809-816. doi: https://doi.org/10.1007/s00198-010-1524-7.

31. Kanis JA, Johansson H, Oden A, et al. A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk. J. Bone Miner. Res. 2004;19(6):893899. doi: https://doi.org/10.1359/jbmr.040134.

32. Staa TPv, Staa TPv, Staa TPv, et al. The Epidemiology of CorticosteroidInduced Osteoporosis: a Meta-analysis. Osteoporos. Int. 2002;13(10):777-787. doi: https://doi.org/10.1007/s001980200108.

33. Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos. Int. 2018;29(12):2585-2596. doi: https://doi.org/10.1007/s00198-018-4650-2.

34. Leslie WD, Johansson H, McCloskey EV, et al. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J. Bone Miner. Res. 2018;33(11):1923-1930. doi: https://doi.org/10.1002/jbmr.3538.

35. Baleanu F, Bergmann P, Hambye AS, et al. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort. Int. J. Clin. Pract. 2019;73(5):e13347. doi: https://doi.org/10.1111/ijcp.13347.

36. Johansson H, Oden A, Johnell O, et al. Optimization of BMD Measurements to Identify High Risk Groups for Treatment-A Test Analysis. J. Bone Miner. Res. 2004;19(6):906-913. doi: https://doi.org/10.1359/jbmr.2004.19.6.906.

37. Tosteson ANA, Melton LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos. Int. 2008;19(4):437-447. doi: https://doi.org/10.1007/s00198-007-0550-6

38. Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos. Int. 2011;23(1):75-85. doi: https://doi.org/10.1007/s00198-011-1747-2.

39. Leslie WD, Majumdar SR, Lix LM, et al. High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos. Int. 2011;23(1):391-397. doi: https://doi.org/10.1007/s00198-011-1592-3.

40. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 2007;18(8):1033-1046. doi: https://doi.org/10.1007/s00198-007-0343-y.

41. Kyriakos G, Vidal-Casariego A, Fernández-Martínez MN, et al. Impact of the NOGG and NOF Guidelines on the Indication of Bone Mineral Density in Routine Clinical Practice. J. Clin. Densitom. 2015;18(4):533-538. doi: https://doi.org/10.1016/j.jocd.2015.08.001.

42. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official Positions of the International Society for Clinical Densitometry. J. Clin. Densitom. 2004;7(1):1-5. doi: https://doi.org/10.1385/jcd:7:1:1.

43. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008;43(6):1115-1121. doi: https://doi.org/10.1016/j.bone.2008.08.106.

44. Shepherd JA, Blake GM. T-Scores and Z-Scores. J. Clin. Densitom. 2007;10(4):349-350. doi: https://doi.org/10.1016/j.jocd.2007.08.006.

45. Watts NB, Leslie WD, Foldes AJ, Miller PD. 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J. Clin. Densitom. 2013;16(4):472-481. doi: https://doi.org/10.1016/j.jocd.2013.08.001.

46. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneva.

47. Kelly TL. Bone mineral density reference databases for American men and women. . Bone Miner. Res. 1990;5(S2):S249. doi: https://doi.org/10.1002/jbmr.5650051302.

48. Hanson J. Standardization of Femur BMD. J. Bone Miner. Res. 1997;12(8):1316-1317. doi: https://doi.org/10.1359/jbmr.1997.12.8.1316.

49. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467-475. doi: https://doi.org/10.1016/j.bone.2007.11.001.

50. Melton LJ, Chrischilles EA, Cooper C, et al. Perspective how many women have osteoporosis? J. Bone Miner. Res. 2009;7(9):1005-1010. doi: https://doi.org/10.1002/jbmr.5650070902.

51. McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J. Bone Miner. Res. 2016;31(5):940-948. doi: https://doi.org/10.1002/jbmr.2734.

52. Gallagher JC, Sai AJ. Is screening for secondary causes of osteoporosis worthwhile? Nature Reviews Endocrinology. 2010;6(7):360-362. doi: https://doi.org/10.1038/nrendo.2010.86.

53. Barzel US. Recommended testing in patients with low bone density. J. Clin. Endocrinol. Metab. 2003;88(3):1404-1405; author reply 1405.

54. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of Laboratory Testing to Identify Secondary Contributors to Osteoporosis in Otherwise Healthy Women. J. Clin. Endocr. Metab. 2002;87(10):4431-4437. doi: https://doi.org/10.1210/jc.2002-020275.

55. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet. 1996;348(9041):1535-1541. doi: https://doi.org/10.1016/s0140-6736(96)07088-2.

56. Cummings SR. Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>. JAMA. 1998;280(24):2077. doi: https://doi.org/10.1001/jama.280.24.2077.

57. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000 Aug 31;343(9):604-10. doi: https://doi.org/10.1056/NEJM200008313430902

58. Saag K, Emkey R, Schnitzer T et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Obstetrical & Gynecological Survey. 1999;54(1):39-40. doi: https://doi.org/10.1097/00006254-199901000-00021

59. McClung MR, Geusens P , Miller PD , et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.N Engl J Med. 2001; 344: 333-340

60. Boonen S, Orwoll E, Wenderoth D, Stoner K, Eusebio R, Delmas P. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study. Journal of Bone and Mineral Research. 2009;24(4):719-725. doi: https://doi.org/10.1359/jbmr.081214

61. Eastell R, Devogelaer J, Peel N et al. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International. 2000;11(4):331-337. doi: https://doi.org/10.1007/s001980070122

62. Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

63. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res. 2005 Aug;20(8):1315-22. Epub 2005 Mar 14.

64. Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, Rowell L, Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010 Mar;46(3):660-5. doi: https://doi.org/10.1016/j.bone.2009.11.004.

65. Harris S, Blumentals W, Miller P. Ibandronate and the risk of nonvertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2007;24(1):237-245. doi: https://doi.org/10.1185/030079908x253717

66. Black D, Delmas P, Eastell R et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22 DOI: https://doi.org/10.1056/NEJMoa067312

67. Boonen S, Reginster J, Kaufman J et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine. 2012;367(18):1714-1723

68. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11;373(9671):1253-63. doi: https://doi.org/10.1016/S0140-6736(09)60250-6

69. Kenneth W. Lyles, Cathleen S. Colón-Emeric, M.H.Sc., Jay S. Magaziner, et al for the HORIZON Recurrent Fracture Trial* Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007;357:1799-1809

70. McClung M, Miller P, Recknor C, Mesenbrink P, BucciRechtweg C, Benhamou C. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology. 2009;114(5):999-1007. doi: https://doi.org/10.1097/aog.0b013e3181bdce0a

71. Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: https://doi.org/10.1056/NEJMoa1808082

72. Cummings S, Martin J, McClung M et al. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: https://doi.org/10.1056/NEJMoa0809493

73. Langdahl B, Teglbjærg C, Ho P et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. The Journal of Clinical Endocrinology & Metabolism. 2015;100(4):1335-1342. doi: https://doi.org/10.1210/jc.2014-4079

74. Orwoll E, Teglbjærg C, Langdahl B et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):3161-3169. doi: https://doi.org/10.1210/jc.2012-1569

75. Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF. Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, doubleblind, double-dummy trial. Arthritis Rheumatol. 2019 Feb 28. doi: https://doi.org/10.1002/art.40874

76. Gnant M, Pfeiler G, Dubsky P et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2015;386(9992):433-443. doi: https://doi.org/10.1016/s0140-6736(15)60995-3

77. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; DenosumabHALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: https://doi.org/10.1056/NEJMoa0809003

78. Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network. Osteoporos Int. 2016 Jun;27(6):1989-98. doi: https://doi.org/10.1007/s00198-015-3476-4

79. McClung M. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. Current Osteoporosis Reports. 2006;4(1):28-33. doi: https://doi.org/10.1007/s11914-006-0012-7

80. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза – применение моноклональных человеческих антител к RANKL (Деносумаб) // Остеопороз и Остеопатии. 2011. – Т.14. - №2. – С. 19-22. doi: https://doi.org/10.14341/osteo2011223-26

81. Miller P, Bolognese M, Lewiecki E et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229. doi: https://doi.org/10.1016/j.bone.2008.04.007

82. Mandema JW1, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a doseresponse-based meta-analysis.J Clin Endocrinol Metab. 2014 Oct;99(10):3746-55. doi: https://doi.org/10.1210/jc.2013-3795.

83. Brown J, Prince R, Deal C et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research. 2009;24(1):153-161. doi: https://doi.org/10.1359/jbmr.0809010

84. Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2016 Oct 13. doi: https://doi.org/10.1002/jbmr.3019.

85. Kendler D, Roux C, Benhamou C et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009;25(1):72-81. doi: https://doi.org/10.1359/jbmr.090716.

86. Tsai J, Uihlein A, Burnett-Bowie S et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2014;30(1):39-45. doi: https://doi.org/10.1002/jbmr.2315.

87. Neer R, Arnaud C, Zanchetta J et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41 doi: https://doi.org/10.1056/NEJM200105103441904

88. Gallagher J, Genant H, Crans G, Vargas S, Krege J. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. The Journal of Clinical Endocrinology & Metabolism. 2005;90(3):1583-1587. doi: https://doi.org/10.1210/jc.2004-0826

89. Orwoll E, Scheele W, Paul S et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Miner Res. 2003;18(1):9-17. doi: https://doi.org/10.1359/jbmr.2003.18.1.9.

90. Saag K, Shane E, Boonen S et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39 DOI: https://doi.org/10.1056/NEJMoa071408

91. Liu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med. 2017;40(3):E146-E157. doi: https://doi.org/10.25011/cim.v40i3.28394.

92. Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6970. doi: https://doi.org/10.1097/MD.0000000000006970.

93. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-240. doi: https://doi.org/10.1016/S0140-6736(17)32137-2

94. Body J, Gaich G, Scheele W et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2002;87(10):4528-4535. doi: https://doi.org/10.1210/jc.2002-020334.

95. Hadji P, Zanchetta J, Russo L et al. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures. Bone. 2011;48:S82-S83. doi: https://doi.org/10.1016/j.bone.2011.03.108.

96. Miller PD, Shergy WJ, Body J, Chen P, Rohe ME, Krege JH.: Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatology. 2005;32:1556-1562.

97. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007

98. European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate). 25 April 2013 EMA/258269/2013

99. European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions. 15 April 2014 EMA 235924/2014

100. Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl. J. Med. 2004;350(12):1189–99. doi: https://doi.org/10.1056/NEJMoa030897.

101. Adler R, El-Hajj Fuleihan G, Bauer D et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. doi: https://doi.org/10.1002/jbmr.2708

102. Black DM, Boonen S, Cauley JA, Cummings SR, Lippuner K, Leung PC, Martinez RLM, Ruzycky ME, Eastell R (2012a) Erratum: The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT). J Bone Miner Res. 27(12):2612,

103. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZONpivotal fracture trial (PFT). J Bone Miner Res. 30(5): 934-944

104. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open- label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23

105. Bone HG, Bolognese MA, Yuenn CK, Kendler DL, Miller PD, Yang YC, Grazette L, Martin JS, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 96(4):972-980

106. Bone HG, Chapurlat R, Brandi ML, et al. (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 98(11):4483-4492

107. Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tremollieres FA, Goulis DG Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101; 23030

108. Белая Ж.Е., Bilezikian J.P., Ершова О.Б., и др. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаба и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП) // Остеопороз и остеопатии. 2018. – Т. 21. – №1. – С. 17-22. doi: https://doi.org/10.14341/osteo9760

109. Brown J, Roux C, Törring O et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013;28(4):746-752. doi: https://doi.org/10.1002/jbmr.1808.

110. Popp A, Zysset P, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporosis International. 2015;27(5):1917-1921. doi: https://doi.org/10.1007/s00198-015-3458-6.

111. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, BurnettBowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386(9999):1147-1155

112. Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017 Jan;35(1):91-98. doi: https://doi.org/10.1007/s00774-015-0731-x

113. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzales-Macies J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C.: Treatment failure in osteoporosis. Osteoporosis Int. 2012;(23):2769-2774

114. Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporosis International. 2011;23(5):1489-1501. doi: https://doi.org/10.1007/s00198-011-1824-6.

115. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455-466. doi: https://doi.org/10.1016/j.jocd.2013.08.004.

116. Marcus R, Wang O, Satterwhite J, Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2003;18(1):18-23. doi: https://doi.org/10.1359/jbmr.2003.18.1.18.

117. Saag K, Zanchetta J, Devogelaer J et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism. 2009;60(11):3346-3355. doi: https://doi.org/10.1002/art.24879

118. British Orthopaedic Association and British Geriatrics Society. The care of patients with fragility fracture. 2007:15-50.

119. Griffiths R, Alper J, Beckingsale A et al. Management of proximal femoral fractures 2011. Anaesthesia. 2011;67(1):85-98. doi: https://doi.org/10.1111/j.1365-2044.2011.06957.x.

120. Загородний Н.В., Голухов Г.Н., Волна А.А. и др. Диагностика и лечение переломов проксимального отдела бедра у лиц пожилого и старческого возраста. Методические рекомендации. РУДН. Москва, 2012.

121. Roche J. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005;331(7529):1374-0. doi: https://doi.org/10.1136/bmj.38643.663843.55.

122. Oliver D, Connelly J, Victor C et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334(7584):82-82. doi: https://doi.org/10.1136/bmj.39049.706493.55

123. Schmidt K, Hübscher M, Vogt L, et al. Einflüsse einer Wirbelsäulenorthese auf Gangparameter und Alltagsfunktion bei Postmenopausaler Osteoporose [Influence of spinal orthosis on gait and physical functioning in women with postmenopausal osteoporosis]. Orthopade. 2012;41(3):200-205. doi: https://doi.org/10.1007/s00132-011-1867-6

124. Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil. 2004; 83:177–186.

125. Yuan Zhe Jin, Jae Hyup Lee Effect of Brace to Osteoporotic Vertebral Fracture: A Meta- Analysis//J Korean Med Sci 2016; 31: 1641-1649.

126. Valentin GH, Pedersen LN, Maribo T. Wearing an active spinal orthosis improves back extensor strength in women with osteoporotic vertebral fractures. Prosthet Orthot Int. 2014;38(3):232-238. doi: https://doi.org/10.1177/0309364613497393

127. Matussek J, Boluki D, Füssel S, Grifka. Orthotic methods for osteoporosis and osteoporotic vertebral fracture. J. Orthopade. 2010;39(4):387-96. doi: https://doi.org/10.1007/s00132-010-1596-2.

128. Shariatzadeh H, Modaghegh BS, MD, Mirzaei A. The Effect of Dynamic Hyperextension Brace on Osteoporosis and Hyperkyphosis Reduction in Postmenopausal Osteoporotic Women. Arch Bone Jt Surg. 2017;5(3):181–185.

129. Snow-Harter C, Bouxsein ML, Lewis BT, Carter DR, Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res. 1992;(7):761-769

130. Vainionpää A, Korpelainen R, Leppäluoto J, Jämsä T. Effects of highimpact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int. 2005;16(2):191-7

131. Kelley G, Kelley K, Tran Z. Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Individual Patient Data. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2002;57(9):M599-M604. doi: https://doi.org/10.1093/gerona/57.9.m599.

132. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., и др. Клинические рекомендации Российской Ассоциации Эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых // Проблемы эндокринологии. 2016. - Т. 62. - №4. - С. 60-84. doi: https://doi.org/10.14341/probl201662460-84

133. Химический состав пищевых продуктов, используемых в Российской Федерации. Доступен по ссылке: http://web.ion.ru/food/FD_tree_grid.aspx.

134. Boonen S, Bischoff-Ferrari H, Cooper C et al. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence. Calcified Tissue International. 2006;78(5):257-270. doi: https://doi.org/10.1007/s00223-005-0009-8.

135. Richy F, Dukas L, Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis. Calcified Tissue International. 2008;82(2):102-107. doi: https://doi.org/10.1007/s00223-008-9102-0.

136. Baber R, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: https://doi.org/10.3109/13697137.2015.1129166.

137. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333

138. Ettinger B, Ensrud K, Wallace R et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial. Obstetrics & Gynecology. 2004;104(3):443-451. doi: https://doi.org/10.1097/01.aog.0000137833.43248.79.

139. T.J. de Villiers, J.E. Hall, J.V. Pinkerton, S. Cerdas Perez, M. Rees, C. Yang, D.D. Pierroz Revised global Consensus Statement on Menopausal Hormone Therapy. J. Climacteric 2016 19:4; 313-315

140. Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375-82

141. Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Mineral Research 2000; 15(4): 721-39.

142. McLellan A, Reid D, Forbes K, et al. Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03): NHS Quality Improvement Scotland. 2004.

143. Akesson K., Marsh D., Mitchell P.J. et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013;24(8): v2135-2152.

144. Hagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 2012; 90: 14-21.

145. Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457-60.

146. Nakayama A., Major G., Holliday E., Attia J., Bogduk N. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016; 27(3): 873-9.

147. Marsh D., Akesson K., Beaton D. E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051-2065.

148. Ganda K., Mitchell P.J., Seibel M.J. Chapter 3 - Models of Secondary Fracture Prevention: Systematic Review and Metaanalysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33-62

149. Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2013;24(2):393–406.